

**AYRTON DRUG MANUFACTURING LIMITED**  
**UN-AUDITED STATEMENT OF FINANCIAL POSITION** AS  
**AT 30TH JUNE 2016**

	<b>30/06/2017</b>	<b>30/06/2016</b>
	<b>GHC</b>	<b>GHC</b>
Revenue	35,016,640	38,772,241
Cost of sales	<u>(16,773,196)</u>	<u>(21,018,854)</u>
		-
<b>Gross profit</b>	<b>18,243,444</b>	<b>17,753,387</b>
		-
Other income	193,896	1,109,352
Exchange Loss/(Gain)	-	-
Selling and distribution costs	(4,896,998)	(5,549,641)
Administrative expenses	<u>(9,115,749)</u>	<u>(7,854,153)</u>
		-
<b>Operating (Profit)/loss</b>	<b>4,424,594</b>	<b>5,458,945</b>
		-
Finance income	-	-
Finance costs	(1,206,109)	(2,215,182)
Impairment loss on investment		-
		-
<b>(Profit)/loss before tax</b>	<b>3,218,485</b>	<b>3,243,763</b>
		-
Income tax expense	<u>(679,289)</u>	<u>(645,522)</u>
		-
<b>(Profit)/loss after tax</b>	<b>2,539,196</b>	<b>2,598,241</b>
Earnings per share	0.0118	0.0121

**AYRTON DRUG MANUFACTURING LIMITED****UN-AUDITED STATEMENT OF FINANCIAL POSITION  
FOR THE FOURTH QUARTER ENDING 30TH JUNE, 2017**

	30/06/2017	30/06/2016
	GHC	GHC
<b>Non current assets</b>		
Property, plant and equipment	6,780,791	7,238,719
Prepaid lease and land	373,261	381,975
Intangible	17,062	53,418
Deferred tax assets	-	-
	<b>7,171,113</b>	<b>7,674,112</b>
<b>Current assets</b>		
Inventories	11,291,765	10,232,050
Trade and other receivable	11,046,426	8,640,992
Current taxation	-	408,803
Cash and bank	125,676	311,380
<b>Total Current Assets</b>	<b>22,463,867</b>	<b>19,593,225</b>
<b>Total Assets</b>	<b>29,634,981</b>	<b>27,267,338</b>
<b>Equity and liabilities</b>		
<b>Equity</b>		
Issued capital	4,475,000	4,475,000
Other capital reserve	1,739,436	1,739,436
Income surplus	11,812,762	9,273,567
	<b>18,027,198</b>	<b>15,488,003</b>
<b>Non-current liabilities</b>		
Deferred tax		-
<b>Current liabilities</b>		
Trade and other payable	4,102,999	5,467,648
Intercompany	1,036,406	1,033,337
Deferred tax Liability	154,459	154,459
Income tax payable	68,900	-
Short term borrowings	6,245,019	5,123,892
<b>Total Liabilities</b>	<b>11,607,783</b>	<b>11,779,335</b>
<b>Total Equity and liabilities</b>	<b>29,634,981</b>	<b>27,267,338</b>

**Signed**  
**Director**  
**Yaw Opare-Asamoah**

**Signed**  
**Director**  
**Nik Amarteifio**

# AYRTON DRUG MANUFACTURING LIMITED

## UN-AUDITED STATEMENT OF CHANGES IN EQUITY FOR THE FOURTH QUARTER ENDING 30TH JUNE, 2017

	Stated capital	Retained Earnings	Other Reserves	Total
	GH¢'000	GH¢'000	GH¢'000	GH¢'000
Period ended 30 June 2017				
At 1 JULY 2016	4,475,000	9,273,567	1,739,436	15,488,003
Profit/(Loss) for the year		2,539,196		2,539,196
Reversal during the year	-	-	-	-
<b>At 30 June 2017</b>	<b>4,475,000</b>	<b>11,812,762</b>	<b>1,739,436</b>	<b>18,027,198</b>
Period ended 30 June 2016				
At 1 JULY 2015	4,475,000	6,675,326	1,739,436	12,889,762
Profit/(Loss) for the year		2,598,241		2,598,241
Reversal during the year				-
<b>At 30 June 2016</b>	<b>4,475,000</b>	<b>9,273,567</b>	<b>1,739,436</b>	<b>15,488,003</b>

**AYRTON DRUG MANUFACTURING LIMITED**  
**UN-AUDITED CASH FLOW STATEMENT**  
**FOR THE FOURTH QUARTER ENDING 30TH JUNE, 2017**

	<b>30/06/2017</b>	<b>30/06/2016</b>
	<b>GH¢</b>	<b>GH¢</b>
<b>OPERATING ACTIVITIES</b>		
Operating (loss)/profit before tax	3,218,485	3,243,763
<b>Adjustment</b>		
Depreciation and amortisation	1,499,627	1,426,034
Write off of property, plant and equipment	-	-
Stock write off	-	513,670
Bad debts written off	-	-
Investment written off	-	-
Unrealised exchange loss/(Gain)	-	(577,322)
Profit / loss on disposal	(34,500)	(26,729)
Interest income	-	(750)
Interest expense	1,206,109	2,215,182
<b>Operating cash flow before working capital changes:</b>	<b>5,889,721</b>	<b>6,793,847</b>
(Increase)/Decrease in inventories	(1,059,715)	1,010,731
(Increase)/Decrease in trade and other accounts receivable	(2,395,169)	1,211,847
Increase/(Decrease) in trade and other accounts payable	(1,371,844)	(2,833,944)
<b>Operating cash flow before interest and tax</b>	<b>1,062,993</b>	<b>6,182,481</b>
Interest received	-	750
Interest paid	(1,206,109)	(2,215,182)
Income tax paid	(201,586)	(321,916)
<b>Net cash flows from operating activities</b>	<b>(344,702)</b>	<b>3,646,133</b>
<b>INVESTING ACTIVITIES</b>		
Purchase of property, plant and equipment	(996,628)	(961,661)
Purchase of intangible asset	-	-
Proceeds from disposal	34,500	95,666
<b>Net cash flows used in investing activities</b>	<b>(962,128)</b>	<b>(865,995)</b>
<b>FINANCING ACTIVITIES</b>		
Dividends paid to equity holders	-	-
Net receipts from short term borrowings	-	-
<b>Net cash flows used in financing activities</b>	<b>-</b>	<b>-</b>
Net decrease in cash and cash equivalents	(1,306,831)	2,780,138
Cash and cash equivalents at beginning	(4,812,512)	(7,592,650)
<b>Cash and cash equivalents at close of the year</b>	<b>(6,119,343)</b>	<b>(4,812,512)</b>